Lundbeck has posted a healthy set of financials for the third quarter this morning with revenues being driven again by its antidepressant blockbuster Cipralex.

Operating profit came in at 846 million Danish kroner, about $159 million, up 7.9% on the like, year-earlier period. Revenues reached 3.62 billion kroner, a rise of 7.5% at constant exchange rates.

Sales of Cipralex (escitalopram) climbed 11% to 1.39 billion kroner while the US version of the drug, sold by licensee Forest Laboratories, had sales of 566 million kroner, down 6%. The Alzheimer's disease drug Ebixa (memantine) climbed 9% to 597 million kroner, while sales of Azilect (rasagiline), for Parkinson’s disease, leapt 28% to 250 million kroner.

Xenazine (tetrabenazine) for the treatment of chorea associated with Huntington's disease, had sales of 172 million kroner, up 92%, while the recently-launched Sabril (vigabatrin) for the treatment of refractory complex partial seizures and the treatment of infantile spasms, contributed 52 million kroner.

Chief executive Ulf Wiinberg said "strong momentum continues in our day-to-day business", noting that "recently we have taken several steps to improve our business outlook", including the in-licensing of Merck & Co's antipsychotic Sycrest (asenapine) and the filing of escitalopram in Japan.

For the full year, Lundbeck now expects revenues of 14.6-14.8 billion kroner and operating profit of 3.3-3.4 billion kroner, up on previous guidance and well up on last year. However the picture for 2012-2014, when escitalopram patents expire, does not look so rosy.

The Danish drugmaker expects to generate a minimum annual revenue and operating profit of  14 billion kroner and 2 billion kroner, respectively, for the 2012-2014 period, way down on recent years. However, Mr Wiinberg, was upbeat, saying "we believe we have laid out a solid platform for the floor guidance and continue to plan for growth from 2015 and onwards".